A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin

NCT01388335 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Lymphoma, Malignant

Interventions

DRUG: warfarin
DRUG: enzastaurin

Sponsor

Eli Lilly and Company